BBIO — BRIDGEBIO PHARMA INC

Ownership history in Eagle Health Investments LP  ·  3 quarters on record

This page tracks every 13F SEC filing in which Eagle Health Investments LP reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
4.36% (2025 Q4)
Avg. % of fund
3.55%
First filed
2025 Q2
Last filed
2025 Q4
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 259,300 — 0% 4.36% $19.8M $76.49
2025 Q3 UNCHANGED 259,300 — 0% 3.54% $13.5M $51.94
2025 Q2 INITIATED 259,300 — — 2.76% $11.2M $43.18
% of Fund (quarterly)    BBIO price (monthly, adj. close)

Other funds also holding BBIO

As of 2025 Q4 — sorted by position size

Aisling Capital Management LP 3Y 7Y 81.29% Kohlberg Kravis Roberts & Co. L.P. 3Y 7Y 16.22% Frazier Life Sciences Management, L.P. 3Y 7.28% First Turn Management, LLC 5.2% BOONE CAPITAL MANAGEMENT LLC 3Y 4.44% Monashee Investment Management LLC 3Y 7Y 4.31% Cormorant Asset Management, LP 3Y 7Y 4.24% Atle Fund Management AB 3Y 7Y 3.45% Laurion Capital Management LP 3Y 7Y 3.28% FARALLON CAPITAL MANAGEMENT LLC 3Y 7Y 3.25%
← Back to Eagle Health Investments LP Holdings